Senicapoc: Preliminary Phase IIa data

Top-line data from 31 evaluable patients in a double-blind, U.K. Phase IIa trial showed that senicapoc missed the primary endpoint of reducing late asthmatic response ( LAR) to an inhaled allergen cha...